

Interferon therapy shifts natural killer subsets among Egyptian patients with chronic hepatitis C

[Amal Fathy](#), [Mohamed Mohy Eldin](#), [Lobna Metwally](#), [Mohamed Eida](#), [Marwa Abdel-Rehim](#), [Gamal Esmat](#)

ABSTRACT

[Natural killer](#) cells can be divided into five subpopulations based on the relative expression of CD16 and CD56 markers. The majority of [natural killer](#) cells are CD56dim, which are considered to be the main cytotoxic effectors. A minority of the [natural killer](#) cells are CD56bright, and function as an important source of immune-regulatory cytokines. Shifts of these subsets have been reported in patients with [chronic hepatitis C](#) virus infection. We sought to investigate the shift of [natural killer](#) subsets among Egyptian patients with chronic HCV and to analyze the influence of interferon therapy on this shift. We applied a flow cytometric analysis of [peripheral blood natural killer](#) subsets for 12 interferon-untreated and 12 interferon-treated patients with chronic HCV, in comparison to 10 control subjects. Among interferon-untreated patients, there was a significant reduction of CD56-16+ (immature natural killer) cells. Among interferon-treated patients, the absolute count of [natural killer](#) cells was reduced, with expansion of the CD56bright subset and reduction of the CD56dim16+ subset. [Natural killer](#) subset counts were not significantly correlated to HCV [viral load](#) and were not significantly different among interferon responders and non-responders. In conclusion, HCV infection in Egyptian patients has been observed to be statistically and significantly associated with reduction of the CD56-16+NK subset, while a statistically significant expansion of CD56bright and reduction of CD56dim16+ subsets were observed after interferon therapy. Further studies are required to delineate the molecular basis of interferon-induced shift of [natural killer](#) subsets among patients with HCV.